NCT04797988已完成不适用
Eon® Flanks Safety Clinical Study Protocol
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- Safety Evaluation eon® treatment of the flanks (Adverse Events)
研究概览
简要总结
This study is designed to provide objective evidence regarding the safety of eon® treatment of the flanks.
详细描述
This study is designed to provide objective evidence regarding the safety of eon® treatment of the flanks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is a healthy male or female > 18 years or older seeking treatment for unwanted fat in the flanks.
- •Subject must be able to read, understand and sign the Informed Consent Form (ICF) in English.
- •Subject has sufficient thickness (≥ 20 mm) of adipose tissue on the flanks area.
- •Subject must be willing and able to adhere to the treatment and follow-up visit schedule.
- •Subject is willing to have photographs and ultrasound measurements taken of the treated area.
- •Female subjects must be using medically acceptable form of birth control during the entire course of the study or may be post-menopausal, or surgically sterilized.
排除标准
- •• Subject had an aesthetic fat reduction procedure in the treatment area within the previous year
- •Subject was pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in last 6 months
- •Subject has an infection, dermatitis or a rash in the treatment area.
- •Subject has tattoos or jewelry in the treatment area or within the treatment area site or photography frame.
- •Subject has a history of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- •Subject has a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- •Subject has a history of a known bleeding disorder.
- •Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light.
- •Subject has known collagen, vascular disease or scleroderma.
- •Subject has undergone a surgery or procedure in the treatment area within 6 months of treatment, which is still healing.
- •Subject suffers from significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy.
- •Subject is undergoing systemic chemotherapy for the treatment of cancer.
- •Subject is using gold therapy for disorders such as rheumatologic disease or lupus.
- •Subject has participated in a study of another device or drug within three months prior to enrollment or during the study.
- •As per the investigator's discretion, the subject has any physical or mental condition which might make it unsafe for the subject to participate in this study.
- •Subject has ongoing use of steroids or secondary rheumatoid drugs.
- •Subject is actively taking psychotropic medications.
结局指标
主要结局
Safety Evaluation eon® treatment of the flanks (Adverse Events)
时间窗: 2 weeks
Adverse Events will be assessed to include ultrasound evaluations with a single expert sonographer identifying the pre-treatment versus Week 2 post-treatment.
次要结局
- Subject Satisfaction(2 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
EPIONE Guided Lung EvaluationLung CancerNCT05651867Quantum Surgical25
Unknown
4 期
A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and PresbyopiaHyperopiaPresbyopiaMyopiaNCT02112968Technolas Perfect Vision GmbH97
Unknown
4 期
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIKMyopiaHyperopiaPresbyopiaNCT01977807Technolas Perfect Vision GmbH100
Unknown
4 期
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIKMyopiaHyperopiaNCT02071576Technolas Perfect Vision GmbH42
已完成
4 期
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) InfectionHIV InfectionsNCT02569502Hoffmann-La Roche6